Biotechnology stocks have been back in the spotlight since the beginning of the year. Successes in research and market approvals for new drugs could provide fresh impetus. Is the sector worth a look now?
Artikel zu “Amgen”
Biotechnology shares ready to stage a comeback?
In the first half of 2023, growth shares – and as such, also the biotechnology sector – came under pressure as investors were pivoting towards value shares. But the signs are changing. The possible high in interest rates in Europe and the USA could boost biotech shares again, as ERSTE STOCK BIOTEC fund manager Harald Kober explains in an interview.
Despite correction: long-term upward trend of biotech companies intact
Biotechnology shares have seen better times. Despite the most recent corrections, hopes for growth in the biotechnology sector remain very high. We spoke to Harald Kober, fund manager of ERSTE STOCK BIOTEC, about the latest developments.